Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRAmework-01 phase 3 study of sofetabart mipitecan in platinum-resistant and platinum-sensitive ovarian cancer
2025-522255-25-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- May 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 27
01
Overview
Phase 3, randomised, open-label trial of sofetabart mipitecan in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (6 arms), sponsored by Eli Lilly and Company. Primary endpoint: Progression-free survival. Planned start May 2026; status: authorised.
02
Drugs
sofetabart mipitecan
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2025-522255-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522255-25-00.